Joinn Laboratories (China) Co (SHSE:603127) GF Value : ¥59.42 (As of May. 08, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-08), Joinn Laboratories (China) Co's share price is ¥18.00. Joinn Laboratories (China) Co's GF Value is ¥59.42. Therefore, Joinn Laboratories (China) Co's Price-to-GF-Value for today is 0.30.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Joinn Laboratories (China) Co is Significantly Undervalued.

Joinn Laboratories (China) Co (SHSE:603127) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Joinn Laboratories (China) Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	18.00	/	59.42
	=	0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co GF Value Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (SHSE:603127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

06127:Hong Kong

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines